Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Universe Pharmaceuticals	Viridian Therapeutics	Oxford BioDynamics	Pediapharm	ReNeuron Group
Symbol	NYSE:UPC	NASDAQ:VRDN	LON:OBD	CVE:PDP	LON:RENE
Price Information
Current Price	$2.97	$16.24	GBX 57.60	C$0.30	GBX 117.84
52 Week Range	N/A	Buy	N/A	N/A	N/A
MarketRank™
Overall Score	0.0	1.5	0.5	0.5	0.6
Analysis Score	0.0	3.5	0.0	0.0	0.0
Community Score	0.0	3.3	2.4	2.5	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.0	0.6	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	N/A	Buy	N/A	N/A	N/A
Consensus Price Target	N/A	$34.00	N/A	N/A	N/A
% Upside from Price Target	N/A	109.36% upside	N/A	N/A	N/A
Trade Information
Market Cap	$64.16 million	$62.53 million	£53.96 million	C$66.36 million	£66.25 million
Beta	N/A	N/A	N/A	N/A	N/A
Average Volume	2,513,845	47,992	137,868	100,369	243,535
Sales & Book Value
Annual Revenue	N/A	$1.05 million	£456,000.00	C$11.16 million	£112,000.00
Price / Sales	N/A	60.44	116.92	5.95	598.29
Cashflow	N/A	N/A	GBX 12.25 per share	C$0.01 per share	GBX 30.95 per share
Price / Cash	N/A	N/A	4.70	23.08	3.81
Book Value	N/A	($15.55) per share	GBX 14.70 per share	C($0.01) per share	GBX 20.80 per share
Price / Book	N/A	-1.04	0.04	-23.08	0.06
Profitability
Net Income	N/A	$-110,710,000.00	N/A	N/A	N/A
EPS	N/A	($11.49)	GBX (4.70)	C($0.07)	GBX (45.90)
Trailing P/E Ratio	0.00	N/A	N/A	N/A	N/A
Forward P/E Ratio	∞	N/A	∞	∞	∞
P/E Growth	N/A	N/A	N/A	150.00	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	N/A	-1,934.14%	N/A	N/A	N/A
Return on Assets (ROA)	N/A	-64.01%	N/A	N/A	N/A
Dividend
Annual Payout	N/A	N/A	N/A	C$0.14	N/A
Dividend Yield	N/A	N/A	N/A	46.67%	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.20%	3.98%	186.87%	11.98%
Current Ratio	N/A	7.39%	10.01%	1.12%	1.77%
Quick Ratio	N/A	7.39%	9.59%	0.71%	1.77%
Ownership Information
Institutional Ownership Percentage	0.38%	N/A	N/A	N/A	N/A
Insider Ownership Percentage	N/A	8.70%	N/A	N/A	N/A
Miscellaneous
Employees	N/A	26	37	N/A	62
Shares Outstanding	21.75 million	3.91 million	92.56 million	221.19 million	56.86 million
Next Earnings Date	N/A	8/4/2021 (Estimated)	6/15/2021 (Estimated)	N/A	7/19/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	ReNeuron Group plc - Update for hRPC therapy candidate study proactiveinvestors.co.uk - June 9 at 12:33 PM
	ReNeuron now expects hRPC study data in fourth quarter proactiveinvestors.co.uk - June 9 at 12:33 PM
	Update for hRPC therapy candidate study sharesmagazine.co.uk - June 9 at 7:33 AM
	ReNeuron Group (LON:RENE) Stock Passes Below 50-Day Moving Average of $134.33 americanbankingnews.com - May 27 at 3:00 AM
	ReNeuron hires new chief scientific officer as it grows pipeline shareprices.com - May 20 at 8:21 AM
	ReNeuron appoints new chief scientific officer proactiveinvestors.co.uk - May 20 at 3:21 AM
	ReNeuron Group plc - Appointment of Chief Scientific Officer proactiveinvestors.co.uk - May 20 at 3:21 AM
	ReNeuron signs new collaboration agreements sharecast.com - March 19 at 1:02 PM
	AIM WINNERS & LOSERS: Futura Medical up on EU medical device clearance lse.co.uk - March 19 at 8:00 AM
	ReNeuron inks commercial collaboration deals for exosome platform lse.co.uk - March 19 at 8:00 AM
	ReNeuron unveils new collaborations, data findings on exosome technology platform proactiveinvestors.co.uk - March 19 at 8:00 AM
	ReNeuron jumps after unveiling new collaborations on exosome technology platform proactiveinvestors.co.uk - March 19 at 8:00 AM
	ReNeuron begins search for new chief financial officer proactiveinvestors.co.uk - March 12 at 8:52 PM
	ReNeuron Group plc - Appointment of Joint Broker proactiveinvestors.co.uk - February 25 at 3:59 AM
	Exosome Diagnostic and Therapeutics Market 2021 to 2025 Growth Factors, Market Characteristics, Opportunities By Type Analysis and Forecast marketwatch.com - February 16 at 7:00 AM
	ReNeuron Group plc - Total Voting Rights proactiveinvestors.co.uk - February 1 at 12:24 PM
	Clinical update - Treatment of first patient cohort completed in Phase 2a extension of retinal disease study pharmiweb.com - January 15 at 4:34 PM
	Notification of Allowance granted for US patent pharmiweb.com - December 17 at 3:06 PM
	Director Deals - Reneuron Group PLC (RENE) stockmarketwire.com - December 16 at 11:02 PM
	Reneuron Share News (RENE) lse.co.uk - December 11 at 2:32 PM
	UK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support Study lse.co.uk - November 25 at 10:19 PM
	ReNeuron Group plc - Interim Results proactiveinvestors.com - November 25 at 10:19 PM
	ReNeuron Group plc - Second Price Monitoring Extn proactiveinvestors.co.uk - November 24 at 6:04 PM
	ReNeuron raising up to £15mln to fund two key R&D programmes proactiveinvestors.co.uk - November 24 at 8:03 AM
	Stem Cells Market Size to Rake USD 17.79 Billion by 2027 arnnet.com.au - October 29 at 7:56 AM

Date	Company	Brokerage	Action
1/25/2021	Viridian Therapeutics	LADENBURG THALM/SH SH	Initiated Coverage
1/20/2021	Viridian Therapeutics	Jefferies Financial Group	Boost Price Target
6/16/2020	Oxford BioDynamics	Shore Capital	Reiterated Rating

(Data available from 6/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources